4 views left Get unlimited views with a free account

Explore the latest trends and actionable insights on the Sarcopenia Pipeline Drugs to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Sarcopenia by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 63 ongoing clinical trials involving Sarcopenia
Of the 63 trials,40 trials are in Phase II
Furthermore, 12 trials are in Phase IV

Number of ongoing Clinical Trials (for drugs) involving Sarcopenia by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Sarcopenia, a musculoskeletal disorder. The largest number of ongoing clinical trials for Sarcopenia is conducted in the Asia-Pacific region. Europe and North America are among some of the other prominent regions engaged in Sarcopenia-related drug trials.

Sarcopenia related clinical trial sponsor

Aarhus University, University of Birmingham, Pusan National University Yangsan Hospital, Beijing Hospital, and Austin Health are among other notable clinical trial sponsors involved in Sarcopenia. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Sarcopenia

Diclofenac potassium and metaxalone (Mobisel) is a key marketed drug involving Sarcopenia.

Diclofenac potassium and metaxalone (Mobisel) is a fixed dose combination, diclofenac potassium is a benzene acetic acid derivative with antipyretic and analgesic properties, acts as antiinflammatory agent and metaxalone is a oxazolidinone derivative, acts as muscle relaxant. It functions via Prostaglandin G/H Synthase 1 (Cyclooxygenase 1 or COX1 or Prostaglandin Endoperoxide Synthase 1 or Prostaglandin H2 Synthase 1 or PTGS1 or EC 1.14.99.1) Inhibitor; Prostaglandin G/H Synthase 2 (Cyclooxygenase 2 or COX2 or Prostaglandin Endoperoxide Synthase 2 or PHS II or Prostaglandin H2 Synthase 2 or PTGS2 or EC 1.14.99.1) Inhibitor mechanism of action. The combination product is formulated as tablet for oral route of administration. Mobisel is indicated for the treatment of pain associated with musculoskeletal disorders, including rheumatoid arthritis, osteoarthritis, psoriatic arthritis, gout, ankylosing spondylitis and sarcopenia. Mobisel is marketed in India by Selvok Pharmaceutical Co.

Explore the latest trends and actionable insights on the Sarcopenia Pipeline Drugs to inform business strategy and pinpoint opportunities and risks. Explore the latest trends and actionable insights on the Sarcopenia Pipeline Drugs to inform business strategy and pinpoint opportunities and risks. Visit Report Store